Review maps GLP-1 receptor agonist evidence in psychiatric populations

The wire

1. 01A review published October 17 in European Archives of Psychiatry and Clinical Neuroscience examines GLP-1 receptor agonists moving from metabolic care into psychiatric evidence.
2. 02Psychiatrists increasingly encounter patients on incretins for antipsychotic-associated weight gain and metabolic syndrome, making the evidence boundary clinically relevant.
3. 03It is a narrative review rather than new trial data; readers should check the underlying studies it cites before drawing conclusions about psychiatric endpoints.

From the source

GLP-1 receptor agonists in psychiatry: from metabolic care to psychiatric evidence

European archives of psychiatry and clinical neuroscience · 2026 Oct 17 · Zhang Y, Qian X, Yin J et al.